Understanding the mechanisms of nanomedicine absorption from the lungs and the application of this knowledge to improving the delivery of chemotherapeutic nanomedicines towards primary and secondary lung cancers

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1022732

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The administration of chemotherapeutic 'nanomedicines' via the lungs has the capacity to improve the specific delivery of toxic anti-cancer drugs specifically towards primary and metastatic lung cancers. This project aims to evaluate how nanomedicines are absorbed from the lungs after an inhaled dose, and how they can be best developed as inhaled chemotherapeutics for the treatment of lung cancers.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Career Development Fellowships

Funding Amount: $408,388.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmaceutical Sciences

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug delivery | lung cancer | lung permeability | lymphatic absorption | nanotechnology

Related Links